Myomo, Inc. (NYSEAMERICAN:MYO – Get Free Report) saw a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 4,720,037 shares, an increase of 38.3% from the January 15th total of 3,411,768 shares. Approximately 12.9% of the shares of the company are sold short. Based on an average daily trading volume, of 597,938 shares, the days-to-cover ratio is presently 7.9 days. Based on an average daily trading volume, of 597,938 shares, the days-to-cover ratio is presently 7.9 days. Approximately 12.9% of the shares of the company are sold short.
Analyst Ratings Changes
Separately, Ascendiant Capital Markets reduced their price objective on Myomo from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday, November 21st. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $7.67.
Myomo Stock Performance
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of MYO. AIGH Capital Management LLC lifted its holdings in shares of Myomo by 22.3% during the 2nd quarter. AIGH Capital Management LLC now owns 3,555,742 shares of the company’s stock worth $7,680,000 after acquiring an additional 649,053 shares during the period. R Squared Ltd acquired a new position in shares of Myomo during the 2nd quarter worth $29,000. Stratos Wealth Partners LTD. lifted its position in shares of Myomo by 380.0% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 60,000 shares of the company’s stock worth $130,000 after buying an additional 47,500 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Myomo during the 4th quarter worth $64,000. Finally, Jefferies Financial Group Inc. acquired a new stake in Myomo in the fourth quarter valued at about $641,000. Institutional investors own 44.99% of the company’s stock.
About Myomo
Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.
Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.
Recommended Stories
- Five stocks we like better than Myomo
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.
